Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

Cancer (Impact Factor: 4.9). 09/2008; 113(5):921 - 929. DOI: 10.1002/cncr.23685
Source: PubMed

ABSTRACT BACKGROUND.There are limited effective treatment options available and a poor 5-year survival for patients with inoperable neuroendocrine liver metastases (NETLMs). In this study, the authors prospectively assessed the safety and efficacy of treatment with yttrium 90 (90Y) radioactive microspheres for patients with unresectable NETLMs.METHODS.Radioactive 90Y resin microspheres (selective internal radiation [SIR-Spheres]) were administered through a temporarily placed percutaneous hepatic artery catheter concomitantly with a 7-day systemic infusion of 5-fluorouracil to patients with progressive, unresectable NETLMs. Patients were monitored prospectively, and the response to treatment was measured by using cancer markers and tumor size on computed tomography imaging studies.RESULTS.Thirty-four patients (22 men) with a mean age 61 years (range, 32-79 years) who had unresectable NETLMs were treated between December 2003 and December 2005. The mean (±standard error) follow-up was 35.2 ± 3.2 months. The site of the primary neuroendocrine tumor was the bronchus in 1 patient, the medullary thyroid in 2 patients, gastrointestinal in 15 patients, the pancreas in 8 patients, and of unknown origin in 8 patients. The tumors were classified as vipoma (1 tumor), somatostatinoma (1 tumor), glucagonoma (2 tumors), large cell (3 tumors), carcinoid (25 tumors), and of unknown origin (2 tumors). Complications after 90Y radioembolization included abdominal pain, which was mild to severe; nausea and fever; and lethargy that lasted from 1 week to 1 month. Two patients developed biopsy-proven radiation gastritis, 1 patient developed a duodenal ulcer, and there was 1 early death from liver dysfunction and pneumonia. Subjective changes from recorded baseline hormone symptoms were reported every 3 months. Symptomatic responses were observed in 18 of 33 patients (55%) at 3 months and in 16 of 32 patients (50%) at 6 months. Radiologic liver responses were observed in 50% of patients and included 6 (18%) complete responses and 11 (32%) partial responses, and the mean overall survival was 29.4 ± 3.4 months). In patients who had evaluable chromogranin A (CgA) marker levels, there was a fall in CgA marker levels after 90Y radioembolization in 19 patients (26%) at 1 month, in 19 patients (41%) at 3 months, in 15 patients (43%) at 6 months, in 11 patients (42%) at 12 months, in 8 patients (38%) at 24 months, and in 3 patients (46%) at 30 months.CONCLUSIONS.In this open study of 34 patients, the results demonstrated that radioembolization with 90Y resin microspheres can achieve relatively long-term responses in some patients with nonresectable NETLMs. Cancer 2008. © 2008 American Cancer Society.

  • Source
    • "(Jakobs 2008) Clinical manifestations of liver dysfunction were noted in 2 of 34 patients (6%) who developed jaundice following treatment with SIR-Spheres for metastatic neuroendocrine tumors in a series by King et al with a median follow up of 35.2 months, and clinical radiation hepatitis was noted in 1 of 46 patients (2%) treated with SIR-Spheres in a series by Lim et al with a median follow up of 9.8 months. (King 2008, Lim 2005) Previous studies have reported a wide range of the incidence of elevated liver function tests following treatment with SIR-Spheres, and our series lies well within the reported range of complications. Of note, of patients with an elevation "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to estimate the incidence of complications after (90)Y microsphere radioembolization for unresectable hepatic tumors and evaluate risk factors for late complications. A cohort of 112 consecutive patients from two institutions underwent (90)Y microsphere radioembolization for unresectable hepatic tumors. Complications were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. Symptoms secondary to postradioembolization syndrome occurring within 30 days were recorded as early complications, and all other complications were considered late complications. Seventy-eight patients (70%) experienced postradioembolization syndrome, including fatigue, abdominal pain, nausea, vomiting, anorexia, or fever. Three patients (3%) experienced a Grade 3 early complication; no Grade 4 or 5 early toxicity occurred. Two patients (2%) experienced clinically significant liver dysfunction; 13 patients (12%), 27 patients (24%), and 9 patients (8%) had an elevation of bilirubin, aspartate aminotransferase, and alanine aminotransferase, respectively. Eleven patients (10%) experienced gastrointestinal ulceration, including two Grade 3 complications and one Grade 4 complication. Cholecystitis occurred in 7 patients (6%), including two Grade 3 complications. Grade 2 pancreatitis occurred in 1 patient (1%). No radiation pneumonitis was observed. The cumulative incidence of late Grade 3 or 4 complications at 12 months after radioembolization was 8%. No Grade 5 toxicity occurred. (90)Y microsphere radioembolization is a well-tolerated treatment for unresectable hepatic tumors with a low risk of Grade 3 or higher early or late toxicity.
    Brachytherapy 08/2013; 12(6). DOI:10.1016/j.brachy.2013.05.008 · 1.99 Impact Factor
  • Source
    • "ORR resulted in 50% and 54%, and stable disease in 44% and 38.5%, respectively. Projected median survival times were 28 and 22 months, respectively (not statistically significant difference), with the majority of patients alive at time of study publication [22]. The largest retrospective study to date reviewed a total of 148 patients in 10 clinical centers treated with Yttrium- 90 resin microspheres in a primarily salvage setting of mNET. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Surgical excision remains the preferred treatment for resectable hepatic metastases of neuroendocrine tumors. In cases of more disseminated hepatic disease, transarterial radioembolization with Yttrium-90- (90Y-) labeled microspheres has been demonstrated as a viable option for symptom and locoregional tumor control. On an outpatient basis, radioembolization can be utilized from early line to salvage phases, in various combinations with systemic therapies. Review of available data shows encouraging safety and efficacy profiles for the intraarterial application of 90Y for the treatment of mNETs of the liver. Symptom control and decrease in somatostatin analog use can be achieved, as well as prolonged survival.
    12/2011; 2011:785315. DOI:10.4061/2011/785315
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver resection is associated with prolonged survival in patients with colorectal liver metastases. Unfortunately, only 15–25% of patients with colorectal liver metastases are candidates for surgery at the time of diagnosis of the metastatic disease. To date, the definition of resectability of colorectal liver metastases is based on complete resection and preservation of sufficient future liver remnant (FLR). In patients with unresectable colorectal liver metastases, portal vein embolization (PVE) induces hypertrophy of the FLR and allows safe liver resection. The safety and the usefulness of this procedure have been evaluated in large series of patients with colorectal liver metastases. Depending on the quality of the liver parenchyma, portal vein embolization is recommended for patients whose standardized FLR is less than 20% in normal liver, less than 30% in case of hepatic injury, and less than 40% in case of fibrosis or cirrhosis. The role of PVE has not been specifically evaluated in patients with metastases from other malignancies (neuroendocrine tumor or noncolorectal nonneuroendocrine liver metastases). However, the indications for PVE are dictated by the volume of the FLR and the quality of liver parenchyma, and the guidelines provided for colorectal liver metastases also apply to other types of liver metastases.
Show more